Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142657 | 0.92 | NPC1 (0.75) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL16896918 | 0.87 | NPC1 (0.74) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL14839476 | 0.86 | SMN1; SMN2 (0.70) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL31570065 | 0.86 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL11679930 | 0.86 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL14817534 | 0.86 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9AHPGD | |
| Anisole SCHEMBL6238456 | 0.85 | MAPT (0.68) | MEN1KMT2ANPC1RAB9AUSP2 | |
| SCHEMBL2856692 | 0.85 | HPGD (0.68) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL5806693 | 0.85 | HPGD (0.68) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL1141400 | 0.85 | MTNR1B (0.81) | MEN1KMT2ANPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022114187-A1 | COMPOUND HAVING INHIBITORY ACTION AGAINST EXCESSIVE MITOCHONDRIAL DIVISIONS | 国立大学法人九州大学 | 2022-06-02 | — | — | WO | disclosed |
| US-10322112-B2 | Compound combinations for attenuation of bacterial virulence | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2408863-B1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | PROMEGA CORP (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20170231962-A1 | Compound Combinations for Attenuation of Bacterial Virulence | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-17 | — | — | US | disclosed |
| CN-105143353-B | Disazo pigment composition and method for producing same | 东洋油墨SC控股株式会社 | 2017-03-15 | — | — | CN | disclosed |
| US-9458499-B2 | Nucleic acid binding dyes and uses therefor | PROMEGA CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458499-B2 | Nucleic acid binding dyes and uses therefor | PROMEGA CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160083782-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-03-24 | — | — | US | disclosed |
| US-20160083782-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-03-24 | — | — | US | disclosed |
| CN-105143353-A | Disazo pigment composition and method for producing same | TOYO INK SC HOLDINGS CO LTD | 2015-12-09 | — | — | CN | disclosed |
| WO-2005066132-A1 | THERAPEUTIC AGENTS I | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-1146088-B1 | Method of producing disazo pigment | TOYO INK MFG CO (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-20010041793-A1 | Method of producing disazo pigment | TOYO INK MFG. CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1146088-A1 | Method of producing disazo pigment | Toyo Ink Manufacturing Co. Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-6303762-B1 | COUPLING A TETRAZO BENZIDINES AND A MIXTURE OF N-PHENYLACETOACETAMIDES | TOYO INK MFG. CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| EP-0070521-B1 | PROCESS FOR IMPROVING THE TECHNICAL APPLICATION PROPERTIES OF DISAZO PIGMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-13 | — | — | EP | disclosed |
| EP-0070521-A1 | Process for improving the technical application properties of disazo pigments | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-26 | — | — | EP | disclosed |
| US-4169091-A | Symmetrical and asymmetrical disazo compounds containing a bis-(nitro-aryloxy)alkane middle component | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-09-25 | — | — | US | disclosed |
| US-4116965-A | STYRYL DYESTUFFS CONTAINING CERTAIN AMINO, CYANOPYRIDINE MOIETIES | CIBA-GEIGY CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-3988312-A | TETRAKISAZO DYES | CIBA-GEIGY CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231962-A1 | Compound Combinations for Attenuation of Bacterial Virulence | PNISR, PGLS, QRFPR | MEN1 3990/4885KMT2A 3286/4885NPC1 4739/4885 |
| US-10322112-B2 | Compound combinations for attenuation of bacterial virulence | PNISR, BLVRB, PGLS | MEN1 4469/4885KMT2A 3318/4885NPC1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.